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ABSTRACT
In January 2005, the National Institute for Health and Care Excellence (NICE) in England andWales provided new guidance on the use
of antiosteoporosis therapies for the secondary prevention of osteoporotic fractures. This was shortly followed in the same year by
market authorization of a generic form of alendronic acid within the UK. We here set out to estimate the actual practice impact of
these events among hip fracture patients in terms of antiosteoporosis medication prescribing and subsequent fracture incidence
using primary care data (Clinical Practice Research Datalink) from 1999 to 2013. Changes in level and trend of prescribing and
subsequent fracture following publication of NICE guidance and availability of generic alendronic acid were estimated using an
interrupted time series analysis. Both events were considered in combination within a 1-year “intervention period.” We identiﬁed
10,873 primary hip fracture patients between April 1999 and Sept 2012. Taking into account prior trend, the intervention period was
associated with an immediate absolute increase of 14.9% (95% CI, 10.9 to 18.9) for incident antiosteoporosis prescriptions and a
signiﬁcant and clinically important reduction in subsequent major and subsequent hip fracture: –0.19% (95% CI, –0.28 to –0.09) and
–0.17% (95% CI, –0.26 to –0.09) per 6 months, respectively. This equated to an approximate 14% (major) and 22% (hip) reduction at
3 years postintervention relative to expected values based solely on preintervention level and trend. We conclude that among hip
fracture patients, publication of NICE guidance and availability of generic alendronic acid was temporally associated with increased
prescribing and a signiﬁcant decline in subsequent fractures. © 2016 American Society for Bone and Mineral Research.
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Introduction
Hip fractures are associated with major distress, disability,dependency,(1) and signiﬁcant costs to health and social
care.(2) Hip fracture patients are at increased risk of subsequent
fracture, premature death,(1) and a decline in quality of life that is
comparable to severe neurological diseases.(3) The projected
cost of hip fracture for the year 2025 is approximately $18 billion
in the United States(4) and £1.5 billion in the United Kingdom.(2)
Data from randomized controlled trials (RCTs) have showed
that bisphosphonate treatment is highly effective for the
secondary prevention of osteoporotic fracture,(5) including
among hip fracture patients.(6) This is reﬂected in many clinical
guidelines from around the world that recommend the use of
bisphosphonate for patients having sustained aminimal trauma
fracture.(7) In January 2005, the National Institute for Health and
Care Excellence (NICE) in England and Wales published new
guidance recommending bisphosphonate use as a ﬁrst-line
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therapy for the secondary prevention of osteoporotic fracture.(8)
Moreover, the ﬁrst-time UK market authorization of generic
bisphosphonate alendronic acid occurred in August 2005, after
which the cost of therapy fell substantially.
We therefore aimed to evaluate these “real world” events
within the English and Welsh National Health Service (NHS)
setting in terms of subsequent change in antiosteoporosis
medication prescribing and incidence of clinical outcomes
such prescriptions were intended to prevent; ie, secondary
osteoporotic fractures.
Materials and Methods
Study population and source of data
We used primary care data from the Clinical Practice Research
Datalink (CPRD) for the period 1999 to 2013. CPRD covers
approximately 11.3 million patients from 674 UK practices and
has a current representative coverage of approximately 7% of
the United Kingdom.(9)Mortality data was linked to theOfﬁce for
National Statistics (ONS) database. Primary hip fractures
occurring between April 1, 1999 and September 30, 2012
were identiﬁed using standard UK clinical terminology “READ”
codes (Supplementary Table 1) as deﬁned a priori by two
clinicians with experience in both clinical practice and
epidemiological research into osteoporosis independently
identifying available codes and reaching consensus. To focus
on proximal femoral fractures, subtrochanteric/shaft fractures
were not included. Patients below 60 years of age were
excluded, as were patients with a history of a hip fracture
diagnosis in the preceding 3 years or with less than 3 years of
clinical data from registration. Patients registered in a general
practitioner (GP) practice outside England or Wales were
excluded as guidance pertained only to these countries.
Intervention
Publication of NICE TA 87(8) in January 2005 and the ﬁrst
authorization of generic forms of alendronic acid in August 2005
were consideredas a combined interventionbecauseof their close
temporal proximity.(10)NICE TA 87 gave for the ﬁrst time guidance
on clinical thresholds for prescribing various antiosteoporosis
medications among postmenopausal women having sustained a
clinically apparent osteoporotic fracture (ie, in secondary preven-
tion). It recommended the use of bisphosphonates for the
treatment of women aged 75 years or older without the need for
prior dual-energy X-ray absorptiometry (DXA) scanning. The
authorization of generic alendronic acid led to a substantial
reduction in price, to what is now approximately £1 per month.(11)
Outcomes
The proportion of patients initiating antiosteoporosis medica-
tions within 1 year of their hip fracture was calculated among
treatment-naive patients (no such prescription within prior 6
months). Medications included were oral bisphosphonates,
strontium ranelate, teriparatide, denosumab, and selective
estrogen receptor modulators. Given concerns regarding low
therapy adherence, we also modeled separately the proportion
of patients who received at least one bisphosphonate prescrip-
tion between 10 to 14 months after their hip fracture (excluding
those patients not surviving to 14 months).
To examine the effect on re-fracture, we derived the proportion
of patients (including prevalent users of antiosteoporosis
medications) sustaining a subsequent major (hip, pelvis, proxi-
mal-humerus, rib, spine, orwrist/forearm) fracturewithin 3 yearsof
their primary event. Hip fractures were only included if sustained
between 6 and 36 months so as to avoid counting of re-coding
events. Second hip fracture was also considered separately.
As a sensitivity analysis, we analyzed women separately
because although treatment is typically offered to both genders
following hip fracture, NICE TA 87 guidance pertained only to
women. We repeated analyses excluding patients who either
transferred out or were registered to a practice whose last data
upload was within 1 year (for incident prescriptions time series)
or 3 years (for re-fracture time series) of their primary hip
fracture. We also repeated analyses for subsequent fracture
outcomes stratiﬁed by therapy status at index hip-fracture.
Statistical analysis
We used an interrupted time series approach(12) to estimate
changes in outcomes immediately following the intervention
period while controlling for baseline levels and trends. In order
to take into account temporal changes in the age and sex
structure of the population, wemodeled aggregated data points
in the form of age and sex standardized biannual proportions of
each outcome of interest using segmented linear regression(10):
Yt¼b0þ b1
timetþb2
interventiontþb3
post_int_timetþ et.
Here, Yt is the proportion of index hip fracture patients with the
outcome at time point (ie, 6-month period) t. b0 estimates the
baseline level of the outcome at the beginning of the time series.
b1 estimates the preintervention trend, b2 the change in level
immediately following the intervention, and b3 the change
in postintervention trend. The intervention period spanned a
1-year period, from the beginning of October 2004 to the end of
September 2005. All analyses were therefore based on 11
preintervention data points (April 1999 to September 2004), and
between10 and14postinterventiondatapoints (October 2005 to
September 2012) according to the follow-up time required for
each outcome measure. Full models including all regression
terms and ﬁnal “conservative” models were derived, the latter
by way of removing nonsigniﬁcant terms in a backward
stepwise process (p-entry 0.049; p-exit 0.10). The presence of
autocorrelation was tested using the Durban-Watson test. All
Durban-Watson statistics were close to the value of 2 and above
the higher bound; therefore, we did not reject the null hypothesis
of no autocorrelation.
For ease of interpretation, we expressed regression coefﬁcients
for level and slope in the form of a single estimate of absolute
change between estimated postintervention values and their
counterfactual values(10,13); ie, estimates for the same time point
but based on preintervention level and trend only. We used the
October 2007 to March 2008 time point because the end of
March2008was themiddleof thepostinterventionperiod (for the
fracture time series). All analyses were performed using Stata
v13.1 (Stata Corporation, Inc., College Station, TX, USA).
Results
We identiﬁed 10,873 eligible patients as having sustained
an incident hip fracture within the period April 1999 to
September 2012. There was an increase in the proportion of
men (21.8% versus 25.0%), proportion aged 85 years and older
(41.9% versus 44.3%), severe rated comorbidities (2.4% versus
7.1%), and prior bisphosphonate use (5.8% versus 24.2%)
(Supplementary Table 2).
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Table 1 reports study outcomes by ﬁnancial year. Comparing
years 1999–2000 to 2011–2012, the initiation of antiosteopo-
rosis medication within 12 months increased markedly from
5.4% to 50.3%, although there were signiﬁcant differences by
gender and age band (Fig. 1A, B). The overall increasewasmainly
driven by alendronic acid (Fig. 1C, D). Between 1999–2000 and
2009–2010, the proportion of patients sustaining a subsequent
major or second hip fracture (as deﬁned in Outcomes section)
declined from 6.2% to 4.7%, and 3.4% to 2.1%, respectively.
Results from the interrupted time series analyses are reportedas
derived from parsimonious regression models. Regression coef-
ﬁcients from “full”models are provided in Supplementary Table 4.
Prescription data
We found a preintervention increase in antiosteoporosis
prescriptions of 1.05% per 6 months of the study period, then
a marked step change of 14.9% (95% CI, 10.9 to 18.9; p 0.001)
taking place between preintervention and postintervention
periods (Fig. 2A, Supplementary Table 3). Also found was a
postintervention trend increase of 0.46% per 6 months (95% CI,
–0.05 to 0.96; p¼ 0.075). This equated to an overall estimated
17.2% (95% CI, 11.0 to 23.3) absolute increase in incident
antiosteoporosis use within 1 year of hip fracture for the time
point 3 years following the start of the intervention period
(Table 2), representing an approximate relative increase of 79%.
Similar although slightly lower increases in prescribingwere seen
when restricted to1 bisphosphonate prescriptions between 10
and 14 months (Fig. 2B, Table 2, Supplementary Table 3).
Subsequent major re-fracture and hip re-fracture
The preintervention level of subsequent major re-fracture was
stable at 6.3% (95% CI, 5.9 to 6.8). Following the intervention
there was a signiﬁcant (p¼ 0.001) downward trend by –0.19%
per 6 months (95% CI, –0.28 to –0.09; p¼ 0.001) (Fig. 3A). This
equated to an absolute reduction of –1.0% (95% CI, –1.4 to –0.5)
at 3 years after the start of the intervention period (Table 2), and
an approximate relative 14% decrease. A similar reduction was
demonstrated for subsequent hip fracture (Fig. 3B): an initial
stable rate of 3.8% (95% CI, 3.4 to 4.2) followed by a
postintervention downward trend of –0.17% (95% CI, –0.26 to
–0.09; p¼ 0.001) per 6 months. This equated to an absolute
reduction of –0.9% 3 years following the start of the intervention
period, and an approximate relative reduction of 22%.
The same time series terms were included in ﬁnal models
in sensitivity analyses including only women (results not shown)
and excluding patients with incomplete follow-up (Supplemen-
tary Table 5), with the exception that no trend change was
detected in incident prescriptions and a signiﬁcant step-change
decrease in subsequentmajor fractures was foundwhen patients
with incomplete follow-up were excluded. We report analyses
stratiﬁed by therapy status at time of index hip fracture in
Supplementary Table 6. For patients not on therapy at baseline,
these were the same as for the main analysis. Among prevalent
users, however, there was no signiﬁcant impact of intervention
identiﬁed, although this is likely to have been a consequence of
the much smaller sample size in this subgroup, especially in the
preintervention period.
Discussion
Our study identiﬁes that following the introduction of NICE TA
87 and ﬁrst UK market authorization of generic alendronic
acid, prescriptions of antiosteoporosis medications increased
markedly among hip fracture patients. This was contemporary
Table 1. Outcomes of Interest Following Primary Hip Fracture: Stratiﬁed by Year (n¼ 10,873)
Index hip fracture
Incident
antiosteoporosis
medication
prescription
(1-year)a
1
Bisphosphonate
prescription
(10–14
months)b
Subsequent
major fracture
(3 years)c
Subsequent
hip fracture
(3 years)c
Year (April–March) n n % n % n % n %
1999 861 47 5.7 30 5.0 50 5.8 27 3.1
2000 855 42 5.2 30 4.9 56 6.6 31 3.6
2001 830 65 8.4 49 8.1 54 6.5 34 4.1
2002 861 84 10.5 78 13.4 59 6.9 34 4
2003 878 112 14 87 14.4 56 6.4 34 3.9
2004 817 126 17.1 93 16.6 61 7.5 33 4
2005 841 225 29.9 165 29.7 48 5.7 25 3
2006 825 267 37.1 184 33.8 48 5.8 26 3.2
2007 816 256 36.5 159 30.6 39 4.8 23 2.8
2008 795 290 42.6 167 31.9 47 5.9 25 3.1
2009 756 278 43.6 166 34.3 36 4.8 17 2.3
2010 719 283 46.2 172 34.2 17d 4.6d 7d 1.9d
2011 667 293 50.9 187 39.4
2012d 352d 148d 48.8d
Overall 10,873 2,516 25.9 1,599 21.8 571 6.0 316 3.3
aOnly among treatment-naive primary hip fracture patients (deﬁned as no antiosteoporosis prescription in 6 months prior to index fracture).
bOnly among bisphosphonate treatment na€ıve primary hip fracture patients surviving to 14 months (deﬁned as no bisphosphonate prescription in
6 months prior to index fracture).
cSecond hip fractures only counted between 6 and 36 months.
dBased on months April through September.
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with a signiﬁcant decline in the incidence of subsequent
fractures and estimated hospital costs.
Considering the ofﬁcial and widespread use of NICE guidance
within the NHS, the ﬁnding of signiﬁcantly increased prescribing
following NICE TA 87 is somewhat an expected ﬁnding and is
consistent with previous reports of temporal associations
between NICE publications and the health or prescription
outcomes they were intended to impact.(14,15) Although we did
not disentangle the effect of the NICE TA 87 publication from
availability of generic alendronic acid, the increase in prescrip-
tions across genders and age groups (Fig. 1A, B) and divergence
of alendronic acid versus other types of bisphosphonates
(Fig. 1D) suggests availability of generic therapy was inﬂuential.
Although a decline in subsequent fracture incidence was
concomitant with increased bisphosphonate prescribing, we
have not here been able to establish whether increased
prescribing caused the reduction in subsequent fractures.
Therapy recommendations contained within NICE TA 87 were
based on data from 39 published RCTs,(8)with referencemade to
the Fracture Intervention Trial where the relative risk (RR)
between alendronate versus placebo arms for subsequent “any
clinical” or hip fracture was 0.74 (95% CI, 0.59 to 0.92) and 0.49
(95% CI, 0.23 to 0.99), respectively, among women with an
existing vertebral fracture.(16) Our use of an interrupted time
series approach that controls for baseline level and trend is
considered a strong quasi-experimental modeling strategy,
allowing for “real world” estimation of longitudinal effects when
an RCT is unfeasible.(10,12) The reverse of this ecological
correlation has also been previously demonstrated, ie, recent
increases in hip fracture incidence alongside a reduction in
bisphosphonate use,(17) itself likely due to reports of atypical
femoral fractures associated with long-term bisphosphonate
use. The large number of primary hip fractures and the
generalizability of the CPRD cohort to the general UK
population(9) are further strengths of the analysis.
One main limitation is that changes in outcomes may have
been confounded by events other than the deﬁned interven-
tion.(1,18) In this context, studies from other countries have
identiﬁed downward trends in fracture rates to an extent that is
beyond that attributable to increased bisphosphonate use
alone,(19,20) thereby prompting explanations of other contribu-
tory factors such as changes in BMI, smoking, and vitamin D
status or improvement in falls prevention services. On the other
hand, a signiﬁcant decline in hip fracture incidence in Canada
has previously been reported for the time period 1985 to
2005,(21) predating the era of large-scale antiosteoporosis
medication use and therefore dependent on alternative
explanations than improvement in treatment rates. One such
candidate there suggested was a birth-cohort effect, which may
have been a factor in the observed decline in our study were
such a phenomenon to be concomitant with our deﬁned
intervention period. One issue is the speed of change in
Fig. 1. Descriptive trends among primary hip fracture patients in: (A) antiosteoporosis medication use within 12 months stratiﬁed by gender; (B)
antiosteoporosis medication use within 12 months stratiﬁed by age; (C) antiosteoporosis medication use within 12 months stratiﬁed by type; and (D)
bisphosphonate use within 12 months stratiﬁed by type.
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Fig. 2. (A) Results from segmented linear regression of incident antiosteoporosis medication in the ﬁrst year after index hip fracture and (B) results from
segmented linear regression of bisphosphonate medication use between 10 and 14 months after index hip fracture, among treatment-naive patients at
baseline who survived to 14 months.
Table 2. Estimated Absolute Change in Outcomes Under Study, Associated With the Publication of NICE TA 87 and First UK Market
Authorization of Generic Alendronic Acid
October 2007 to March 2008 estimatea Absolute changea
Outcomes
Without intervention
(%)
With intervention
(%)
Estimate
(%)e
Lower
95% CI
Upper
95% CI
Subsequent antiosteoporosis medication
(0–12 months)b
21.7 38.9 17.2 11.0 23.3
Subsequent bisphosphonate medication
(10–14 months)b,c
19.9 32.1 12.2 6.6 17.7
Subsequent major fractures
(0–36 months)d
6.3 5.4 –1.0 1.4 0.5
Subsequent hip fractures (6–36 months)d 3.8 3.0 –0.9 1.2 0.5
Values calculated by comparing estimated values in the period October 2007 to March 2008 (3 years after the beginning of the intervention phase) to
counterfactual values for the same period (ie, those expected for October 2007 to March 2008 based only on the preintervention level and trend).
aEstimated from ﬁnal/parsimonious models speciﬁed using backward-stepwise selection (p-entry 0.049 and p-exit 0.10). Percentages rounded to one
decimal place.
bAmong treatment-naive index hip fracture patients.
cAmong survivors at 14 months.
dSubsequent hip fractures only counted between 6 and 36 months.
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prescription and re-fracture rates, which suggest that slower
changes in demographics such as obesity are less likely to be the
main cause of the ﬁndings of this study. Furthermore, lack of
association between bisphosphonate use and hip fracture
incidence across Canadian provinces has also recently been
reported,(22) although those data did not distinguish between
primary and secondary prevention of fractures or address the
issue of confounding by indication.
Although the discrete intervention evaluated here was the
publication of NICE guidance and availability of generic
alendronate, other changes in the health care system such as
in the introduction of Fracture Liaison Service (FLS) models of
care(23,24) may also have contributed to the ﬁndings. Given that
the FLS operates to improve case-ﬁnding, assessment, therapy
initiation, and monitoring after a fragility fracture and that such
services have become increasingly common in the NHS, it is
plausible these models of care contributed to the steeper
and sustained postintervention increase in prescribing of the
therapies which were recommended and became substantially
cheaper during the intervention period. An economic evaluation
of an FLS in the UK health setting has shown FLS to be a cost-
effective model for improving secondary fracture prevention
within the United Kingdom,(25) although the fracture reduction
was based on prescribing rates only. Other studies have
reported no observed difference in fracture rates by FLS
status,(26) one possible explanation being poor medication
adherence. Further work is required given the wider availability
of parenteral therapies with signiﬁcantly greater adherence
rates.(27)
It is worth noting that in a post hoc analysis we found our
decline in 3-year re-fracture rate to be occurring in the context of
a stable 3-year mortality rate, although 1-year mortality did
improve over the course of the study period (25.3% versus 19.8%
for years 1999–2000 to 2012–13). However, given that fracture
risk after hip fracture is high, improved survival at 1-year would
likely increase rather than reduce the re-fracture rates as patients
live longer at an elevated risk of re-fracture.(28) Acknowledging
that persistence with bisphosphonates is poor,(29) it is reassuring
that the intervention was associated here with increased
prescribing between 12 and 14 months.
Reporting absolute difference between estimated postin-
tervention values compared to estimated contralateral values
does involve extrapolation and therefore uncertainty, although
95% conﬁdence intervals incorporating the standard error of
regression coefﬁcients are included.(13) We also had more than
the minimum number of eight time points before and after the
Fig. 3. (A) Results from segmented linear regression of subsequent major fracture within 3 years after index hip fracture and (B) results from segmented
linear regression of subsequent hip fracture within 3 years (6–36 months) after index hip fracture.
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intervention to have sufﬁcient power to estimate the regression
coefﬁcients.(30) Main ﬁndings were derived from parsimonious
regression models, but estimated changes in fracture outcomes
were larger when “full” models were used (Supplementary
Fig. 1, Supplementary Table 4). Using routinely collected data
with no individual validation of fracture events is another
limitation; however, validation of hip and vertebral fracture
coding has been carried out previously and has been shown to
be accurate.(31) Our deﬁnition of second hip fracture is based on
previous work(32) and incorporates a 6-month washout from the
index fracture to minimize the inclusion of recoding events,
although such occurrences cannot be ruled out.
Although we set out to investigate the potential impact on
prescribing and the clinical outcomes such prescribing was
intended to improve, we did not model the unintended
consequences of bisphosphonate use. Widespread concern
exists regarding adverse events (eg, gastrointestinal problems)
and safety issues associated with bisphosphonate use, most
notably osteonecrosis of the jaw and atypical fractures.(33)
However, given that the absolute risk of these safety issues is
low at approximately one in 300 patients sustaining an atypical
fracture among those treated for 3 years(34) and the high rate of
discontinuation among bisphosphonate users,(29) we would be
underpowered to investigate such events here. Furthermore,
although we acknowledge that adverse events from the use of
some antiosteoporosis medications are important to include,
there is no READ code for atypical fractures and so this could not
be included in themodel and remains an area for future research.
Our time series of prescriptions data is consistent with secular
trends of similar outcomes reported in the literature.(35) Despite
the observed increase in prescribing, our ﬁndings support
previous reports of undertreatment of high-risk patients,
contrary to guideline recommendations.(36,37) For example, a
national audit within the United Kingdom indicated in 2010 that
40% of hip fracture patients did not receive appropriate bone
health treatment.(38)One caveat here is that we were not able to
consider zoledronic acid use because it is rarely administered in
a primary care setting.
Exact comparison of re-fracture rates to other studies is difﬁcult
because of the difference in deﬁnitions, outcome measures, and
time periods used.(26,39,40) Particularly, our UK cohort of hip
fractures was smaller and our secular trend in re-fracture different
from that reported elsewhere,(41) although in order to be highly
speciﬁc that we included true incident hip fractures, our inclusion
criteria required 3 years’ registration in a CPRD-participating GP
practice and only considered proximal femoral fractures.
However, wemay have created an artiﬁcially stable study sample
with respect to GP practice in only including thosewith 3 years of
GP registration prior to their index hip fracture.
In summary, although this is an observational study and we
have not proven a cause-effect relationship, we have shown that
among hip fracture patients, publication of NICE guidance
and availability of generic alendronic acid was temporally
associated with an increase in antiosteoporosis medication
prescribing and a clinically important reduction in the incidence
of subsequent fracture.
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